Page 134 - 2020年20期

Res，2016. DOI：10.1161/CIRCRESAHA.115.307016. pharmacological targets in COPD and asthma[J]. Eur J
[28] GAO Y，YU C，PI S，et al. The role of P2Y12 receptor in Pharmacol，2006，533（1/3）：89-100.
ischemic stroke of atherosclerotic origin[J]. Cell Mol Life [41] LI Z，DELANEY MK，O'BRIEN KA，et al. Signaling dur-
Sci，2019，76（2）：341-354. ing platelet adhesion and activation[J]. Arterioscler Thro-
[29] ANGIOLILLO DJ，ROLLINI F，STOREY RF，et al. Inter- mb Vasc Biol，2010，30（12）：2341-2349.
national expert consensus on switching platelet P2Y12 re- [42] USTA C，TURGUT NT，BEDEL A. How abciximab
ceptor-inhibiting therapies[J]. Circulation，2017，136（20）： might be clinically useful[J]. Int J Cardiol，2016. DOI：
1955-1975. 10.1016/j.ijcard.2016.07.213.
[30] JEON YT，YANG W，QIAO JX，et al. Identification of [43] ZHU G，ZHANG Q，REDDY EC，et al. The integrin PSI
1-{2-[4-chloro-1′-（2，2-dimethylpropyl）-7-hydroxy-1，2- domain has an endogenous thiol isomerase function and is
dihydrospiro[indole-3，4′-piperidine]-1-yl]phenyl}-3-{5- a novel target for antiplatelet therapy[J]. Blood，2017，129
chloro-[1，3]thiazolo[5，4-b]pyridin-2-yl}urea，apotent，ef- （13）：1840-1854.
ficaciousand orally bioavailable P2Y1 antagonist as an an- [44] NIEMANMT. Protease-activated receptors in hemosta-
tiplatelet agent[J]. Bioorg Med Chem Lett，2014，24（5）： sis[J]. Blood，2016，128（2）：169-177.
1294-1298. [45] CUNNINGHAM M，MCINTOSH K，BUSHELL T，et al.
[31] YEUNG J，LI W，HOLINSTAT M，et al. Platelet signaling Proteinase-activated receptors（PARs）as targets for anti-
and disease：targeted therapy for thrombosis and other re- platelet therapy[J]. Biochem Soc Trans，2016，44（2）：
lated diseases[J]. Pharmacol Rev，2018，70（3）：526-548. 606-612.
[32] XIANG Q，PANG X，LIU Z，et al. Progress in the develop- [46] WIVIOTT SD，STEG PG. Clinical evidence for oral anti-
ment of antiplatelet agents：focus on the targeted molecu- platelet therapy in acute coronary syndromes[J]. Lancet，
lar pathway from bench to clinic[J]. Pharmacol Ther， 2015，386（9990）：292-302.
2019. DOI：10.1016/j.pharmthera.2019.107393. [47] WILSON SJ，ISMAT FA，WANG Z，et al. PAR4（prote-
[33] ESTEVEZ B，DU X. New concepts and mechanisms of ase-activated receptor 4）antagonism with BMS-986120
platelet activation signaling[J]. Physiology：Bethesda， inhibits human ex vivo thrombus formation[J]. Arterio-
2017，32（2）：162-177. scler Thromb Vasc Biol，2018，38（2）：448-456.
[34] NYLANDER S，KULL B，BJÖRKMAN JA，et al. Human [48] KHAN N，FAROOQ AD，SADEK BS. Investigation of cy-
target validation of phosphoinositide 3-kinase（PI3K）β：ef- clooxygenase and signaling pathways involved in human
fects on platelets and insulin sensitivity，using AZD 6482 platelet aggregation mediated by synergistic interaction of
a novel PI3Kβ inhibitor[J]. J Thromb Haemost，2012，10 various agonists[J]. Drug Des Devel Ther，2015. DOI：
（10）：2127-2136. 10.2147/DDDT.S84335.
[35] BIRD JE，SMITH PL，BOSTWICK JS，et al. Bleeding re- [49] KORPORAAL SJA，MOLENAAR TJM，LUTTERS BCH，
sponse induced by anti-thrombotic doses of a phosphoi- et al. Peptide antagonists for P-selectin discriminate be-
nositide 3-kinase（PI3K）-β inhibitor in mice[J]. Thromb tween sulfatide-dependent platelet aggregation and PSGL-
Res，2011，127（6）：560-564. 1-mediated cell adhesion[J]. J Clin Med，2019. DOI：
[36] MURPHY PT，GRACE S，GLAVEY S，et al. Rivaroxaban 10.3390/jcm8081266.
may increase platelet activation in vivo via thromboxane [50] WANG Y，TANG J，ZHU H，et al. Aqueous extract of Rab-
A2[J]. Circ Res，2019. DOI：10.1161/CIRCRESAHA. dosia rubescens leaves：forming nanoparticles，targeting
119.315453. P-selectin，and inhibiting thrombosis[J]. Int J Nanomedi-
[37] SMITH WL，MARNETT LJ，DEWITT DL. Prostaglandin cine，2015. DOI：10.2147/IJN.S91316.
and thromboxane biosynthesis[J]. Pharmacol Ther，1991. [51] LORDAN R，TSOUPRAS A，ZABETAKIS I，et al. Forty
DOI：10.1016/0163-7258（91）90054-p. years since the structural elucidation of platelet-activating
[38] FAN H，CHEN S，YUAN X，et al. Structural basis for li- factor（PAF）：historical，current，and future research per-
gand recognition of the human thromboxane A2 recep- spectives[J]. Molecules，2019. DOI：10.3390/molecules-
tor[J]. Nat Chem Biol，2019，15（1）：27-33. 24234414.
[39] 2019 阿司匹林在心血管疾病一级预防中的应用中国专 [52] 钟晓南.血小板活化因子受体拮抗剂治疗缺血性卒中的
家共识写作组. 2019阿司匹林在心血管疾病一级预防中 中国专家共识[J].中国神经免疫学和神经病学杂志，
的应用中国专家共识[J/OL].中华心血管病杂志：网络 2020，27（1）：1-5、8.
版，2019，2（1）：e1-e9. （收稿日期：2020-04-27 修回日期：2020-09-11）
（编辑：孙 冰）
[40] ROLIN S，MASEREEL B，DOGNÉ JM. Prostanoids as

·2556 · China Pharmacy 2020 Vol. 31 No. 20 中国药房 2020年第31卷第20期